Health tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoption

Reuters

Jan 12

Health tech firm <a href="https://laohu8.com/S/HYPR">Hyperfine</a> prelim Q4 revenue rises 127% on Swoop system adoption

Overview

Health tech firm's preliminary Q4 revenue rises 127% yr/yr, driven by Swoop system adoption
Preliminary Q4 net cash burn down 30% yr/yr
Company exits 2025 with approximately $35 mln in cash and equivalents

Outlook

Hyperfine to provide full 2025 results and 2026 outlook in March 2026 earnings call

Result Drivers

REVENUE GROWTH - Hyperfine's Q4 revenue increased 127% yr/yr, driven by Swoop system adoption in hospitals, neurology offices, and international markets
TECHNOLOGY LAUNCHES - Recent launches of next-gen Swoop System and Optive AI software contributed to Q4 growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales	Beat	$5.30 mln	$5.005 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Hyperfine Inc is $1.65, about 63.4% above its January 9 closing price of $1.01

Press Release: ID:nBw5zSfsSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2602485965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602485965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602485965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602485965","market":"us","top_or_hot":-1,"title":"Health tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoption","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Health tech firm <a href=\"https://laohu8.com/S/HYPR\">Hyperfine</a> prelim Q4 revenue rises 127% on Swoop system adoption</title></head><body><p><span>Overview</span></p><ul><li><p>Health tech firm's preliminary Q4 revenue rises 127% yr/yr, driven by Swoop system adoption</p></li><li><p>Preliminary Q4 net cash burn down 30% yr/yr</p></li><li><p>Company exits 2025 with approximately $35 mln in cash and equivalents</p></li></ul><p><span>Outlook</span></p><ul><li><p>Hyperfine to provide full 2025 results and 2026 outlook in March 2026 earnings call</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE GROWTH - Hyperfine's Q4 revenue increased 127% yr/yr, driven by Swoop system adoption in hospitals, neurology offices, and international markets</p></li><li><p>TECHNOLOGY LAUNCHES - Recent launches of next-gen Swoop System and Optive AI software contributed to Q4 growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Beat</p></td><td><p>$5.30 mln</p></td><td><p>$5.005 mln (2 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Hyperfine Inc is $1.65, about 63.4% above its January 9 closing price of $1.01</p></li></ul><p>Press Release: <span>ID:nBw5zSfsSa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoption</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoption\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Health tech firm <a href=\"https://laohu8.com/S/HYPR\">Hyperfine</a> prelim Q4 revenue rises 127% on Swoop system adoption</title></head><body><p><span>Overview</span></p><ul><li><p>Health tech firm's preliminary Q4 revenue rises 127% yr/yr, driven by Swoop system adoption</p></li><li><p>Preliminary Q4 net cash burn down 30% yr/yr</p></li><li><p>Company exits 2025 with approximately $35 mln in cash and equivalents</p></li></ul><p><span>Outlook</span></p><ul><li><p>Hyperfine to provide full 2025 results and 2026 outlook in March 2026 earnings call</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE GROWTH - Hyperfine's Q4 revenue increased 127% yr/yr, driven by Swoop system adoption in hospitals, neurology offices, and international markets</p></li><li><p>TECHNOLOGY LAUNCHES - Recent launches of next-gen Swoop System and Optive AI software contributed to Q4 growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Beat</p></td><td><p>$5.30 mln</p></td><td><p>$5.005 mln (2 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Hyperfine Inc is $1.65, about 63.4% above its January 9 closing price of $1.01</p></li></ul><p>Press Release: <span>ID:nBw5zSfsSa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HYPR","symbol_name":"Hyperfine","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL1N3YD0GH:1","article_id":"2602485965","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602485965","pubTimestamp":1768224313,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Health tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoptionOverviewHealth tech firm's preliminary Q4 revenue rises 127% yr/yr, driven by Swoop system adoptionPreliminary Q4 net ca","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HYPR":"Hyperfine","BK4082":"医疗保健设备"},"translate_title":"健康科技公司Hyperfine prelim第四季度收入因采用Swoop系统而增长127%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HYPR":0.9},"content_text":"Health tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoptionOverviewHealth tech firm's preliminary Q4 revenue rises 127% yr/yr, driven by Swoop system adoptionPreliminary Q4 net cash burn down 30% yr/yrCompany exits 2025 with approximately $35 mln in cash and equivalentsOutlookHyperfine to provide full 2025 results and 2026 outlook in March 2026 earnings callResult DriversREVENUE GROWTH - Hyperfine's Q4 revenue increased 127% yr/yr, driven by Swoop system adoption in hospitals, neurology offices, and international marketsTECHNOLOGY LAUNCHES - Recent launches of next-gen Swoop System and Optive AI software contributed to Q4 growthKey DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesBeat$5.30 mln$5.005 mln (2 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for Hyperfine Inc is $1.65, about 63.4% above its January 9 closing price of $1.01Press Release: ID:nBw5zSfsSaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}